Why researchers like Alan Kooi Davis — the newest addition to the Johns Hopkins psychedelic research team — decide to devote their careers to studying psychedelics.

We need new drugs. The opioid epidemic gripping the United States has brought into public awareness a problem that has bedeviled the world of medical science for decades: is it possible to have a truly powerful painkiller that is not addictive?

Today, we have a world where we can say: “I’m proud to be a woman” and “I’m proud to be gay.” But we can’t say: “I’m a drug-user.”

A team of researchers bathed octopuses in MDMA. Here's what they learned.

Narratives which gloss-over the history and socioeconomic dynamics of ayahuasca’s globalization may, despite good intentions, actually do more harm than good.

We talked with Johns Hopkins psychedelic researcher, Alan Kooi Davis, about the Source Research Foundation, a non-profit awarding grants to students researching psychedelics.

What does MDMA rescheduling mean for the recreational user? If you are under the impression that MDMA is on its way to being rescheduled, across the board, you may be disappointed.

Until MDMA-assisted psychotherapy is proven without a doubt to reduce long-term costs, many insurance companies do not have an incentive to cover it.

After the murder of a Peruvian healer in 2018, traditional healers, local political figures, and nonprofit allies gathered to address the complexities that come with the influx of foreigners seeking ayahuasca in the Amazon.

The first time I bought a balloon of heroin I was 20 years old. Fresh out of rehab, I was craving opiates—specifically OxyContin.